Amersham gets FDA approval for Irish facility

Contrast-agent developer Amersham Health of the U.K. has received U.S. Food and Drug Administration approval for the manufacturing and packaging of its Omnipaque, Omniscan, and Visipaque products at its production facility in Cork, Ireland. Omnipaque is used for contrast x-ray exams, Omniscan is a general-purpose MRI agent, and Visipaque is a coronary x-ray contrast product.

By AuntMinnie.com staff writers
July 11, 2002

Related Reading

Amersham, Premier extend brachytherapy seed agreements, July 2, 2002

Amersham to market Optison in Europe, June 6, 2002

Amersham inks supply deal with Novation, May 29, 2002

Amersham shows uptick in Q1 numbers, April 29, 2002

Amersham launches online encyclopedia, March 4, 2002

Copyright © 2002 AuntMinnie.com

Page 1 of 3617
Next Page